Katherine Buck, APRN
Family · Norman, OKNPI 1659772986
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (37.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Immunogen, Inc. accounts for 65.4% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2023 at $10,098 and has fallen 84.5% since, to $1,565 in 2025. Among family clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 197 payments — averaging $71.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Immunogen, Inc.$9K
- AstraZeneca$971
- Daiichi Sankyo Inc.$518
- Merck$499
- GSK$467
- Genmab U.S., Inc.$343
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$4,92635%
- Travel & lodging$3,61025%
- Food & beverage$5,32338%
- Education$3002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Immunogen, Inc. | 30 | $9,257 |
| AstraZeneca | 25 | $971 |
| Daiichi Sankyo Inc. | 20 | $518 |
| Merck | 23 | $499 |
| GSK | 11 | $467 |
| Genmab U.S., Inc. | 10 | $343 |
| Myriad Genetic Laboratories, Inc. | 5 | $274 |
| Astellas Pharma US Inc | 9 | $266 |
| Gilead | 2 | $223 |
| AbbVie | 8 | $214 |
| Lilly USA, LLC | 9 | $144 |
| Stemline Therapeutics Inc. | 7 | $129 |
| Eisai Inc. | 5 | $126 |
| E.r. Squibb & Sons, L.L.C. | 1 | $118 |
| Seagen Inc. | 6 | $103 |
| Genentech USA, Inc. | 5 | $93 |
| Tersera Therapeutics LLC | 3 | $71 |
| Novo Nordisk | 3 | $68 |
| Tempus AI, Inc | 2 | $48 |
| Caris MPI, Inc. | 2 | $33 |
| Legend Biotech USA Inc. | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 2 | $28 |
| EMD Serono, Inc. | 1 | $27 |
| Agios Pharmaceuticals, Inc. | 1 | $23 |
| Clovis Oncology, Inc. | 1 | $21 |
| Incyte Corporation | 1 | $21 |
| Novartis | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Geron Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,158 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $9,184 |
| Letrozole | 15 | $1,882 |
| Gabapentin | 38 | $280 |
| Nystatin | 11 | $177 |
| Triamcinolone Acetonide | 16 | $86 |
| Fluconazole | 12 | $61 |
Paid to pharmacies, not to this prescriber.
Other family in Norman
- Jackson LaizureNorman$13K
- Jordan HarrisNorman$12K
- Julie RobersonNorman$10K
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Candy WilliamsTulsa$22K
- Lacey HillOklahoma City$20K
- Shelby WrightStillwater$17K
- Amanda OblanderYukon$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.